MANGALAM DRUGS & ORGANICS LTD. SHARE PRICE [LIVE]
BSE: INE584F01014 NSE: MANGALAM SECTOR: Pharma
Open: | |
High: | |
Low: |
MKT Cap: | |
52-wk High: | |
52-wk Low: |
Prev close: | |
P/E: | |
Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
Name | Mar 21 | Dec 20 |
---|
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in MANGALAM DRUGS & ORGANICS LTD.
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
MANGALAM News
- EKI ENERGY SERVICES LIMITED
- SYNTHIKO FOILS LTD.
- ABM INTERNATIONAL LIMITED
- IFL ENTERPRISES LIMITED
- GEOJIT FINANCIAL SERVICES LTD
- HASTI FINANCE LIMITED
- SHETRON LTD.
- PSP PROJECTS LTD
- MPIL CORPORATION LIMITED
- ELANGO INDUSTRIES LTD.
- MITSHI INDIA LTD
- RAMCO CEMENTS LIMITED
- TATA INVESTMENT CORPORATION LTD
- VIJAY TEXTILES LTD.
- SUBHASH SILK MILLS LTD.
- EASTERN GASES LTD
- PPAP AUTOMOTIVE LIMITED
- METRO BRANDS LIMITED
- RITES LIMITED
- CAPTAIN POLYPLAST LIMITED
Frequently Asked Questions
What is the Share price of MANGALAM DRUGS & ORGANICS LTD. (MANGALAM)?
Can I buy MANGALAM DRUGS & ORGANICS LTD. (MANGALAM) shares?
How do I buy MANGALAM DRUGS & ORGANICS LTD. (MANGALAM) from Angel One?
- Direct investment: You can buy MANGALAM DRUGS & ORGANICS LTD. (MANGALAM) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to MANGALAM DRUGS & ORGANICS LTD. (MANGALAM) shares.
In which sector do MANGALAM DRUGS & ORGANICS LTD. (MANGALAM) belong?
About MANGALAM
Today's live share price for MANGALAM DRUGS & ORGANICS LTD. is NSE: ₹ 149.00, BSE: ₹ 149.00 with a current market capitalization of .
Mangalam Drugs and Organics Ltd is an India-based company. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra. They also have an in-house Research and Development (R&D) Base. Their products include chloroquine phosphate I.P., aluminum chloride anhydrous, and dyes and intermediaries. Mangalam Drugs and Organics Ltd was incorporated on April 18, 1972 as a private limited company with the name Advent Pharma Pvt Ltd. The company was promoted by Dhoot family. The company was established with a view to set up a plant for manufacture of organic and inorganic chemicals. In April 1, 1996 three other group companies, namely Mangalam Organics Pvt Ltd, Shree Mangalam Pharma Pvt Ltd and Mangalam Rasayan Pvt Ltd were amalgamated with the company. In July 1, 1997, the company changed their name from Advent Pharma Pvt Ltd to Mangalam Drugs and Organics Pvt Ltd. In September 22, 1997, the company was converted into a deemed public company and word 'private' was deleted from the company's name. In the year 1999, the company launched a new product namely, Nimesulide. In the year 2001, they launched two new products namely Amodiaquine Hydrochloride and Amodiaquine. In August 10, 2001, the company was converted into a full fledged public limited company. In the year 2003-2004, the bulk drug production capacity of the Company was increased from 350 MTPA to 600 MTPA. During the 2004-05, the capacity is being further enhanced to 960 MTPA. During the year 2005-06, the company further enhanced their Bulk drug production capacity from 960 MT per annum to 1260 MT per annum. During the year 2007-08, the company developed and introduced new bulk drugs namely Bisoprolol Fumarate and Pantaprazole Sodium. Also, they increased the production capacity of Meta Chloro Aniline & Allied Products from 250 tons to 350 tons. During the year 2009-10, the company in addition to Regulatory Affairs Cell established Intellectual Property Rights (IPR) cell. The regulatory affairs cell submitted 6 DMFs to WHO-Geneva out of which 2 DMFs corresponding to Artemether and Lumefantrine had been approved.
Read more